Organon & Co. (NYSE:OGN) Shares Up 4.6% – Time to Buy?

Shares of Organon & Co. (NYSE:OGN) shot up 4.6% during mid-day trading on Monday . The stock traded as high as $12.81 and last traded at $12.77. 676,770 shares traded hands during mid-day trading, a decline of 75% from the average session volume of 2,708,999 shares. The stock had previously closed at $12.20.

Analyst Ratings Changes

Several analysts recently commented on OGN shares. Barclays dropped their target price on Organon & Co. from $26.00 to $24.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. Morgan Stanley dropped their price target on shares of Organon & Co. from $16.00 to $15.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 9th. Finally, TD Cowen raised shares of Organon & Co. to a “hold” rating in a research note on Wednesday, January 15th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $20.60.

Organon & Co. Trading Up 3.4 %

The company has a 50 day simple moving average of $13.86 and a 200 day simple moving average of $15.14. The company has a market capitalization of $3.25 billion, a PE ratio of 3.79, a price-to-earnings-growth ratio of 0.90 and a beta of 0.73. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70.

Organon & Co. (NYSE:OGN) last issued its quarterly earnings results on Thursday, February 13th. The company reported $0.83 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.09). The firm had revenue of $1.59 billion for the quarter, compared to analysts’ expectations of $1.57 billion. Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. Analysts anticipate that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 13th. Stockholders of record on Monday, February 24th were paid a $0.28 dividend. This represents a $1.12 annualized dividend and a dividend yield of 8.88%. The ex-dividend date was Monday, February 24th. Organon & Co.’s dividend payout ratio is currently 33.63%.

Institutional Trading of Organon & Co.

A number of hedge funds have recently bought and sold shares of OGN. Horizon Bancorp Inc. IN lifted its position in Organon & Co. by 2,401.5% during the fourth quarter. Horizon Bancorp Inc. IN now owns 1,651 shares of the company’s stock worth $25,000 after buying an additional 1,585 shares in the last quarter. Millstone Evans Group LLC purchased a new stake in shares of Organon & Co. in the fourth quarter valued at about $29,000. Larson Financial Group LLC raised its stake in Organon & Co. by 345.4% during the fourth quarter. Larson Financial Group LLC now owns 2,236 shares of the company’s stock worth $33,000 after purchasing an additional 1,734 shares during the period. Riverview Trust Co boosted its holdings in Organon & Co. by 117.7% in the 4th quarter. Riverview Trust Co now owns 2,390 shares of the company’s stock valued at $36,000 after purchasing an additional 1,292 shares during the last quarter. Finally, GeoWealth Management LLC purchased a new stake in shares of Organon & Co. in the 4th quarter valued at approximately $41,000. Institutional investors and hedge funds own 77.43% of the company’s stock.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.